Tanshinone IIA affects the malignant growth of Cholangiocarcinoma cells by inhibiting the PI3K-Akt-mTOR pathway
Abstract In the present study, we aimed to find the target of Tanshinone IIA (Tan-IIA) in Cholangiocarcinoma by network pharmacology-based prediction and investigate the possible mechanism through experimental verification. In this study, we combined Tan-IIA-specific and Cholangiocarcinoma-specific...
Main Authors: | Huayuan Liu, Caiyun Liu, Mengya Wang, Dongxu Sun, Pengcheng Zhu, Ping Zhang, Xueying Tan, Guangjun Shi |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-09-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-98948-z |
Similar Items
-
PI3K/AKT/mTOR pathway in Angiogenesis
by: Jayashree eKarar, et al.
Published: (2011-12-01) -
PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities
by: Wojciech Wiese, et al.
Published: (2023-11-01) -
Tanshinone IIA promotes vascular normalization and boosts Sorafenib’s anti-hepatoma activity via modulating the PI3K-AKT pathway
by: Chengdong Qin, et al.
Published: (2023-06-01) -
Targeting PI3K/Akt/mTOR Signaling In Cancer
by: Camillo ePorta, et al.
Published: (2014-04-01) -
PI3K/Akt/mTOR inhibitors in breast cancer
by: Joycelyn JX Lee, et al.
Published: (2015-12-01)